Maria Elisa M.
- Country
- Italy
- Department
- Center for Thrombosis and Hemorrhagic Diseases
Research Overview
- Evaluation of Fitusiran for Bleed Prevention in Patients with Severe Hemophilia A Previously Treated with Emicizumab
- Pharmacokinetic Evaluation of Efanesoctocog Alfa Versus Other Extended Half-Life Recombinant Factor VIII Products in Severe Haemophilia A Patients
- Phase III Randomized Open‑Label Trial of Subcutaneous NXT007 Prophylaxis versus Intravenous Factor VIII Prophylaxis in Patients with Hemophilia A without Inhibitors
Data & Insights
Has run more than one trial at 64 of 137 partner sites.
Specializations
Hemophilia Treatment Innovation
The investigator specializes in evaluating novel therapeutic approaches for hemophilia A and B, with particular focus on preventive treatments and bleeding management protocols.
- Prophylactic therapy assessment
- Extended half-life factor products
- Novel subcutaneous treatments
Their research encompasses both adult and pediatric populations affected by severe forms of hemophilia.
Joint Health Management
Focused on investigating synovial hypertrophy and overall joint status in hemophilia patients, particularly those receiving prophylactic treatment regimens.
- Ultrasound-based joint assessment
- Long-term joint outcomes
- Synovial tissue evaluation
The research extends to monitoring joint health improvements under various treatment protocols.
Perioperative Care
Specializes in perioperative management of hemophilia patients, particularly those undergoing major surgical procedures while maintaining ongoing prophylaxis.
- Surgical hemostasis optimization
- Combined therapy approaches
- Treatment safety monitoring
Emphasis on maintaining effective hemostatic control during surgical interventions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.